Provided by Tiger Trade Technology Pte. Ltd.

WUXI XDC

76.500
+1.6502.20%
Volume:3.38M
Turnover:259.87M
Market Cap:97.00B
PE:68.30
High:77.800
Open:75.200
Low:74.950
Close:74.850
52wk High:85.500
52wk Low:43.500
Shares:1.27B
HK Float Shares:1.27B
Volume Ratio:0.74
T/O Rate:0.27%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.120
ROE:16.33%
ROA:9.32%
PB:7.34
PE(LYR):68.30
PS:11.93

Loading ...

HK Biotech Stocks Fell. Akeso Down 12%; Remegen, Zai Lab, KeyMed And Junshi Down 7%; Lepu And Innocare Down 6%

Tiger Newspress
·
Apr 23

CMB International Reports Moderate Recovery in Healthcare Sector Risk Appetite, Recommends Six Stocks Including Hansoh Pharma

Stock News
·
Apr 20

Assessing WuXi XDC Cayman (SEHK:2268) Valuation After New Akari Therapeutics ADC Partnership

Simply Wall St.
·
Apr 10

Akari CEO says WuXi XDC partnership accelerates AKTX-101 IND toward late 2026

Reuters
·
Apr 09

WUXI XDC Issues 1.203 Million Shares Following Option Exercise

Stock News
·
Apr 08

WuXi XDC approves 4.85 million restricted shares for 425 staff under 2024 scheme

Bulletin Express
·
Apr 08

WuXi XDC files HKEX next-day return, issues 1,507,353 shares at HKD 1.8-7.5

Reuters
·
Apr 08

WuXi XDC grants 4,854,500 nil-cost restricted shares under 2024 scheme

Reuters
·
Apr 08

WuXi XDC Adds 0.84 Million Shares in March 2026 as Pre-IPO Options Are Exercised

Bulletin Express
·
Apr 08

Akari partners with WuXi XDC to accelerate PH1 ADC payload development, IND by 2026

Reuters
·
Apr 06

HK Pharma Stocks Gained. CSPC Pharma Up 13%; Lepu Bio Up 7%; Hengrui Pharma And Junshi Bio Up 6%; HBM, Beigene, Sihuan Pharm Up 5%

Tiger Newspress
·
Mar 27

HK Pharma Stocks Gained. XuanzhuBio Up 9%; Xtalpi, Lepu Bio And Ascletis Up 6%; Akeso Up 5%; Skb Bio Up 4%.

Tiger Newspress
·
Mar 26

CLSA Raises Target Price for WUXI XDC to HK$80.9, Citing Improved Profit Visibility

Stock News
·
Mar 25

CICC Maintains Outperform Rating on WUXI XDC with HK$88.0 Target Price

Stock News
·
Mar 25

WuXi XDC Cayman (SEHK:2268) Margin Slip Tests Bullish Growth Narrative After FY 2025 Earnings

Simply Wall St.
·
Mar 24

Morgan Stanley Assigns "Overweight" Rating to WUXI XDC (02268) with HK$86 Price Target

Stock News
·
Mar 24

From Enabler to Innovator: WUXI XDC's Evolution and Value Transformation in the CRDMO Sector

Stock News
·
Mar 24

Pharmaceutical Sector Leads Hong Kong Market Rebound with Strong ETF Performance

Deep News
·
Mar 24

HK Pharma Stocks Gained. Wuxi XDC Up 8%; Wuxi AppTec Up 7%; Transthera And HBM Up 5%; Keymed Bio And Innocare Up 4%; Wuxi Bio And Remegen Up 3%

Tiger Newspress
·
Mar 24

Stock Track | WUXI XDC Soars 5.22% Intraday on Strong Fiscal Year Results

Stock Track
·
Mar 24